Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV002306039 | SCV002599676 | uncertain significance | not provided | 2022-11-02 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV002306039 | SCV003287199 | uncertain significance | not provided | 2021-12-18 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 17 of the FOXRED1 protein (p.Arg17Gln). This variant is present in population databases (rs148692707, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with FOXRED1-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt FOXRED1 protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003098035 | SCV003745467 | uncertain significance | Inborn genetic diseases | 2021-09-27 | criteria provided, single submitter | clinical testing | The c.50G>A (p.R17Q) alteration is located in exon 1 (coding exon 1) of the FOXRED1 gene. This alteration results from a G to A substitution at nucleotide position 50, causing the arginine (R) at amino acid position 17 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003138162 | SCV003828336 | uncertain significance | Mitochondrial complex 1 deficiency, nuclear type 19 | 2022-12-07 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003138162 | SCV003836314 | uncertain significance | Mitochondrial complex 1 deficiency, nuclear type 19 | 2022-06-14 | criteria provided, single submitter | clinical testing |